Mexico Image-Guided Therapy Systems Market Size & Outlook, 2025-2033
Mexico Image-Guided Therapy Systems Market Insights
- As per Reed Intelligence insights, the Mexico Image-Guided Therapy Systems Market stood at USD 172.73 Million in 2024 and is anticipated to grow to USD 260.61 Million by 2033.
- The Mexico market is expected to advance at a CAGR of 4.69% from 2026 through 2033.
- In 2024, Computed Tomography (CT) Scanners accounted for the highest share of the By Product market size.
- During the forecast period, Single Photon Emission Computed Tomography (SPECT) is set to register the highest growth, making it the most lucrative By Product segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Mexico contributed 3.39% to the global Image-Guided Therapy Systems Market size in 2024.
- By 2033, United States is forecasted to remain the largest global market for Image-Guided Therapy Systems Market.
- In LATAM, Brazil is projected to capture the leading share of market size by 2033.
- Among LATAM markets, Colombia is expected to post the fastest growth, reaching USD 58.06 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 172.73 Million |
| Market Size In 2033 | USD 260.61 Million |
| Largest segment | Computed Tomography (CT) Scanners |
| Units | Revenue in USD Million |
| CAGR | 4.69% (2025-2033) |
| Segmnetation Covered | |
| By Product |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Mexico Image-Guided Therapy Systems Market By Product 2025-2033 (USD Million)
| By Product | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Computed Tomography (CT) Scanners | XX.x | XX.x | XX.x | 48.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ultrasound Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Magnetic Resonance Imaging (MRI) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Endoscope | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| X-ray Fluoroscopy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Positron Emission Tomography (PET) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Single Photon Emission Computed Tomography (SPECT) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Image-Guided Therapy Systems Market By Application 2025-2033 (USD Million)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac Surgery | XX.x | XX.x | XX.x | 49.51 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Neurosurgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Orthopedic Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Urology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gastroenterology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oncology Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
